Clinical trial · Interventional
Study to Evaluate an Oxaliplatin-based Chemotherapy in Patients With Resistant or Relapsing Non-Hodgkin Lymphoma.
NCT01019863CI-TRIAL-00004280LNH-RGDOXunknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluation of the efficacy, tolerance, quality of life and cost effectiveness of the association of Oxaliplatin, Gemcitabine, Rituximab and Dexamethasone for treatment of patients with refractory or relapsing non-Hodgkin lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Hodgkin Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| oxaliplatin | Drug | Oxaliplatin | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Oxaliplatin
- description
- oxaliplatin associated with Rituxan,Gemcitabine, and Dexamethasone in patients with refractory or relapsed Non hodgkinien lymphoma
- interventionNames
- Drug: oxaliplatin
Primary outcomes (1)
- measure
- Response rate to RGDOx in patients with relapsing or refractory NHL
- timeFrame
- Within 3 months after chemotherapy (6-8 cycles)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients 18 years or above at the time of inclusion. 2. Documented CD20+ NHL, refractory or relapsing after first line chemotherapy. 3. No contraindication to Oxaliplatin, Gemcitabine, Dexamethasone or Rituximab. Exclusion Criteria: 1. Other types of non-Hodgkin lymphoma 2. Pregnancy and lactation. 3. Patient unable to give written informed consent. 4. Contra-indication ou intolerance to any of the components of the RGDOx chemotherapy.
References
Publications (0)
Data not yet available
No reference posted for this study.